...Equity analysis of GlaxoSmithKline Submitted to Prof. Latha Ramesh Submitted By: Yateendra Agarwal Registration No: 1220344 Section: D Batch: 2012-2014 Christ University Institute of Management Kengri Campus Established in the year 1924 in India GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 3500 people. Globally, GSK is a £ 27.4 billion, leading, research-based healthcare and pharmaceutical company. In India, it is one of the market leaders with a turnover of Rs. 2699 crore and a share of 4.2%. The GSK India product portfolio includes prescription medicines and vaccines. Our prescription medicines range across therapeutic areas such as anti-invectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases. The company is the market leader in most of the therapeutic categories in which it operates. GSK also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, streptococcus pneumonia and others.GSK's best-in-class field force, backed by a nation-wide network of stockists, ensures that the Company's products are readily available across the nation. GSK has two manufacturing units in India, located at Nashik and Thane as well as a clinical development centre in Bangalore. The state of art plant at Nashik makes formulations while bulk...
Words: 3823 - Pages: 16
...my guide gave me a chance at redemption. I excelled in academics and achieved Department rank two with a CPI of 9.67/10. During senior year I was part of orientation team which worked to enable smooth transition into campus for new students. Morever, I held responsibility as Department placement coordinator and successfully inivited companies from across Inida to hire students of our department. All these experiences ascertainied that I have come a long way since the initial days of my undergraduate studies. I have decided to dedicate myself to research and take up teaching as a profession. Unfortunately, life does not go as planned, my father met with an accident and sustained cerebral hemorrhage during my senior year. I have rejoined Dr.Reddys Laboratories in July/2015 after submitting masters thesis to stay with my family and provide emotional and financial support during these hard times. I am continuing my research on polymorphism and crystallization process development ever since. Now, my father has recovered and I decided to chase my lifelong goal of pursuing PhD and settling down in academics. \paragraph{} I wish to work with \textbf{Prof. Thomas F Edgar} in the area of model predictive control of continuous systems and explore its applications to pharmacuetical industry. \textbf{Prof. Michael Baldea}'s work in the area of modelling, simulation and optimization of complex systems elicits my interest. I am equally fascinated by the work of \textbf{Prof. Roger T. Bonnecaze}...
Words: 1505 - Pages: 7
...A REVIEW OF MARKETING STRATEGIES WORK BY DIFFERENT PHARMACEUTICAL COMPANIES Saurabh Kumar Saxena Department of Management, Rakshpal Bahadur Management Institute Bareilly-243001, India Mail: saxena100rabh@rediffmail.com ABSTRACT The current shift in the marketing strategy is work by multinational pharmaceutical Companies .It is now high-end (rather than adaptive) development that is being carried out by leading companies. And, increasingly, other companies are finding themselves competing against, or working with, new innovation-based companies. My study focuses on the processes and outcomes of globally distributed pharmaceutical companies. This article will present the changing marketing strategies when a pharma company shifts from Acute base to Chronic therapy base. This research paper will also give an insight about shift in supply chain process and customer and end-customer perception which is the base of formulation of different marketing strategies. Key Words: Acute, Chronic, Core, Super Core, Closing stock, Inventory, Push, Pull, End-customer, Core customer, SKUs, SAP, ERP, Primary Sales, Secondary Sales. 1.INTRODUCTION: The pharmaceutical industry is the world’s largest industry due to worldwide revenues of approximately US$2.8 trillion. Pharma industry has seen major changes in the recent years that place new demands on payers, providers and manufacturers. Customers now demand the same choice and convenience from pharma industry that they find in other segment...
Words: 3807 - Pages: 16
...A STUDY OF CAMPUS RECRUITMENT (Term Paper towards partial fulfillment of the assessment in the subject of Human Resource Management) Submitted by: Submitted to: Nikita Gupta Dr. Vedantam Leela Roll Number-- 598 Faculty of Management Semester- IV National Law University, Jodhpur Winter Session (January-May 2010) ACKNOWLEDGMENT ____________________________________________________________ __________________ No work can be perfect without ample guidance. I acknowledge my sincere thanks to Dr. Vedantam Leela, who provided me the opportunity to gain an invaluable knowledge by becoming my project guide. Her dynamic cooperation helped me to excel in this project. I would like to express a deep sense of gratitude and heartiest thanks to the Mrs. Priyanka Agarwal, HR Manager, Inrea Research and the placement-incharge Dr. A.K. Bhatnagar and students of SS Subodh PG College for their help and valuable time they provided me in this project. Cooperation extended by others directly or indirectly for completion of this project is highly acknowledged. Regards! Nikita Gupta (598) TABLE OF CONTENTS ____________________________________________________________ _______________ ACKNOWLEDGMENT ......2 CERTIFICATE ......3 RESEARCH METHODOLOGY ......5 Chapter I: Market Trends of Campus Recruitment ......6 Chapter II: Campus Recruitment: Care and Caution ......12 Chapter III: Introduction to the Company ........
Words: 7448 - Pages: 30
...Term Paper Report On Competitive Marketing Policies & Strategies Of Pharmaceutical Products in Bangladesh Submitted to Mr. Abdus Samad Chowdhury Senior Management Councilor Bangladesh Institute of Management Submitted By MD. MAHAFUZUR RAHMAN ID: 14MM028 Post Graduate Diploma In Marketing Management Date of Submission 21-12- 2014. Bangladesh Institute of Management Department of Marketing Management Letter of Transmittal December 21, 2014 Mr. Abdus Samad Chowdhury Bangladesh Institute of Management Subject: Request to accept my term paper report on competitive marketing policies & strategies of Pharmaceutical Products in Bangladesh. Dear Sir, I have given a topic on “Competitive Marketing Policies & Strategies of Pharmaceutical Products in Bangladesh” for writing a term paper for presentation, collection of primary data and secondary data. To do so, we sought the relevant information from books, newspaper and websites. We also went to many respondents who are closely related this entire process. I tried to collect all possible information and make this paper acceptable to all but there can be still existing mistake. So we like to request you to consider if any fault is found in this paper. Finally I would like to request you to accept our paper and permit us to present it before the panel of experts. Yours Sincerely Md. Mahafuzur Rahman Roll No : 14MM028 Post Graduate Diploma in Marketing Management. Bangladesh...
Words: 9861 - Pages: 40
...A Handbook on Derivatives © Rajkumar .S Adukia B.com (Hons.), L.L.B, AICWA, FCA radukia@vsnl.com/rajkumar@gmail.com 093230 61049/ 093221 39642 www.carajkumarradukia.com If interested in receiving similar technical updates subscribe to carajkumarradukia-subscribe@yahoogroups.com PREFACE Derivatives have changed the world of finance as pervasively as the Internet has changed communications .Well they are everywhere nowadays. The most significant event in finance during the past decade has been the extraordinary development and expansion of financial derivatives. These instruments enhance the ability to differentiate risk and allocate it to those investors who are most able and willing to take it -- a process that has undoubtedly improved national productivity, growth and standards of living. Derivatives products provide certain important economic benefits such as risk management or redistribution of risk away from risk-averse investors towards those more willing and able to bear risk. Derivatives also help price discovery, i.e. the process of determining the price level for any asset based on supply and demand. All markets face various kinds of risks. This has induced the market par-ticipants to search for ways to manage risk. The derivatives are one ofthe categories of risk management tools. As this consciousness about risk management capacity of derivatives grew, the markets for derivatives...
Words: 15288 - Pages: 62
...CONTE N T S CHAI R M A N ’ S LETTE R DEAR SH AREH OL DERS FY2012 has been a good year for your Company. The key financial results were: ¥ Consolidated revenues increased by 30% to Rs. 96.7 billion in FY2012. ¥ Earnings before interest, taxes, depreciation and amortization (EBITDA)1 rose by 55% to Rs. 25.4 billion. ¥ Profit after Tax (PAT)2 grew by 45% to Rs. 15.3 billion. ¥ Diluted Earnings per Share (EPS) increased from Rs. 64.9 in FY2011 to Rs. 83.8 in FY2012. I am particularly delighted by four developments. First, your Company succeeded in yet another blockbuster generic launch in the USA under 180days marketing exclusivity. Dr. Reddy’s launched olanzapine 20 mg tablets, the generic version of the brand Zyprexa®. Olanzapine is used to treat schizophrenia and bipolar disorder. This product has added around USD 100 million to your Company’s revenues for FY2012. Second, the biosimilars business continues along its impressive growth path. In my letter to you last year, I had discussed the critical importance of developing biosimilars in the years to come. I am happy to note that your Company’s global biosimilars business grew by 45% over last year and recorded sales of USD 26 million. Today, the biosimilars portfolio of Dr. Reddy’s constitutes (i) filgrastim, (ii) peg-filgrastim, (iii) rituximab and (iv) darbepoetin alfa, which have commercial presence in 13 countries among emerging markets. These are helping to treat patients suffering from cancer — and at prices that...
Words: 128176 - Pages: 513
...Invest. Innovate. Inspire. For a new India. ANNUAL REPORT 2014-15 India is at the threshold of a new era of growth and opportunity. This is driven by increasing economic activity, ongoing ‘Make in India’ initiatives and a demographically well-placed, aspirational society. Reliance Industries Limited (RIL) continues to be a partner in India’s ongoing journey towards economic and social well-being, and remains committed to investing in and innovating for India. RIL is striving to meet and exceed global benchmarks in product quality and customer service with inspiring ideas and strategic investments. From the manufacturing landscape to high-growth consumer service sectors, RIL is achieving superior outcomes that facilitate India’s drive for global leadership. RIL is delivering industry-leading performance through consistent efficiency in operations and prudent configuration of assets. RIL is making sizable capital investments, focusing on technology and expanding its level of services from the hydrocarbons sector to consumer businesses. RIL innovates for existing businesses and also focuses on developing new business models to deliver g g g y significant value for its growing stakeholder fraternity. In this effort, it collaborates with o s with leading global institutions to help usher in a n era of possibilities. global new is growing o RIL’s focus is to continue growing as a respons responsible organisation, thereby e inspiring progress in...
Words: 182744 - Pages: 731
